



THE ORPHAN ONCOLOGY INNOVATOR

Disclosure of total number of voting rights and number of shares in the capital at September 30, 2014

Paris, October 2, 2014 – Pursuant to article L.233-8 II of the *Code de commerce* (the French Commercial Code) and article 223-16 of the *Règlement général de l’Autorité des Marchés Financiers* (Regulation of the French stock market authority):

Date	Total number of outstanding shares	Total number of voting rights
September 30, 2014	31, 490, 644	Theoretical number of voting rights: 31, 490, 644 (including treasury shares) Number of real voting rights: 31, 484, 294 (without treasury shares)

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.

Key products at advanced development stage are:

Livatag[®] (Doxorubicin Transdrug[™]): Phase III in hepatocellular carcinoma

Validive[®] (Clonidine Lauriad[®]): Phase II in severe oral mucositis

Beleodaq[®] (belinostat): registered in the US in peripheral T-cell lymphoma

For more information, visit the website www.onxeo.com

Contacts :

Judith Greciet, CEO

j.greciet@onxeo.com

+33 1 45 58 76 00

Nicolas Fellmann, CFO

n.fellmann@onxeo.com

+33 1 45 58 76 00

Caroline Carmagnol / Sophie Colin – Alize RP

caroline@alizerp.com / scolin@alizerp.com

+33 6 64 18 99 59 / +33 6 31 13 76 20